Search
Novartis Introduces a Domestic Nuclear Medicine at a Cost of US$900 Million
13 hour ago /
Read about 0 minute
Author：小编
Borui Chuanghe has reached a global exclusive licensing agreement with Novartis to jointly promote the innovative development of a preclinical radioligand therapy. Both parties will leverage their respective expertise in drug discovery, development, and radioligand therapy to provide effective treatment options for patients worldwide. This is not Novartis's first time introducing a domestic nuclear medicine.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
